Related Experiment Videos
Zidovudine-induced fever.
M A Jacobson1, M S McGrath, P Joseph
1Department of Medicine, University of California San Francisco.
Journal of Acquired Immune Deficiency Syndromes
|January 1, 1989
Summary
Zidovudine (AZT) can cause severe fever in AIDS patients, even when other causes are ruled out. This hypersensitivity reaction may involve specific antibodies, highlighting a critical adverse effect of this antiretroviral drug.
Area of Science:
- Immunology
- Pharmacology
- Infectious Diseases
Background:
- Zidovudine (3'-azido-3'deoxythymidine, AZT) was the first antiretroviral medication approved for symptomatic human immunodeficiency virus (HIV) infection.
- While initial trials noted nausea and hematologic toxicity, fever was not a significant reported side effect.
Observation:
- An open-label study indicated that 10% of acquired immune deficiency syndrome (AIDS) patients experienced fever severe enough to warrant halting zidovudine treatment.
- This report details three AIDS patients who developed severe fever attributed to zidovudine, with other potential causes systematically excluded.
Findings:
- Drug rechallenge confirmed zidovudine as the cause of fever in all three described patients.
- One patient exhibited IgM antibodies against a zidovudine-serum protein complex, suggesting a potential immune mechanism.
- The other two patients with zidovudine-induced fever, along with control groups, did not show detectable IgG or IgM anti-zidovudine antibodies.
Implications:
- Zidovudine can induce severe fever as an adverse effect in AIDS patients, potentially mediated by Type III or Type IV hypersensitivity reactions.
- This finding underscores the importance of monitoring for idiosyncratic drug reactions, including fever, in patients undergoing antiretroviral therapy.
- Further research into the immunological basis of zidovudine-induced fever may inform safer treatment strategies for HIV/AIDS.